Triple-negative breast cancer trials in Argentina
6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Córdoba, Mar del Plata, Mendoza, Rosario, Viedma
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Buenos Aires, Córdoba, Mar del Plata, Rosario, San Miguel de Tucumán, San Salvador de Jujuy
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Buenos Aires, Capital Federal, Ciudad Autónoma de Buenos Aires, Rosario
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - Phase 3Taking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Buenos Aires, Caba, La Plata, Rosario, San Juan, San Miguel de Tucumán, Viedma
- Age
- 18 years and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - Phase 3Taking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- CABA, Ciudad Autónoma Buenos Aires, Ciudad de Buenos Aires, Rosario, San Nicolás de los Arroyos
- Age
- 18 years and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - Phase 2/3Taking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- ABB, Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Mendoza, Río Cuarto, Rosario
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00